| アブストラクト | INTRODUCTION: While antipsychotic-induced weight gain has been widely described in adults, it has yet to be better characterized in children and adolescents. OBJECTIVE: The aim of this study was to assess antipsychotic-induced weight-gain reporting in children and adolescents as compared to adults, and according to the type of antipsychotic. METHODS: The study is an observational, case-non-case study using individual case safety reports from the WHO global pharmacovigilance database VigiBase((R)) from 1 January 2000 to 2 June 2021. Disproportionality in antipsychotic-related weight-gain reporting in children and adolescents compared to adults was evaluated based on reporting odds ratios (RORs) with corresponding 95% confidence intervals (CIs) through multivariate logistic regression modeling. Analysis was adjusted for sex, region of reporting, year of notification, reporter qualification, concomitant use of antidepressants, and use of more than one antipsychotic. RESULTS: Among 282,224 antipsychotic-related spontaneous reports included in this analysis, we identified 16,881 (6.0%) weight-gain cases. Disproportionality in weight-gain reporting was found in children (adjusted ROR (aROR) 3.6; 95% CI 3.3-3.8) and in adolescents (aROR 2.3; 95% CI 2.2-2.4) compared to adults. Use of risperidone was associated with the highest increase in weight-gain reporting in children (aROR 4.9; 95% CI 3.9-6.1) and adolescents (aROR 3.6; 95% CI 3.1-4.1). CONCLUSIONS: Compared to adults, weight-gain reporting with antipsychotics was disproportionally higher in the pediatric population, especially in children under 12 years of age. Considering the impact of weight gain on global morbidity and mortality, physicians should closely monitor weight gain in young patients, especially children on risperidone. |
|---|
| 投稿者 | Kaguelidou, Florentia; Valtuille, Zaba; Durrieu, Genevieve; Delorme, Richard; Peyre, Hugo; Treluyer, Jean-Marc; Montastruc, Francois; Chouchana, Laurent |
|---|
| 組織名 | Department of Pediatric Pharmacology, APHP.Nord, Robert Debre Hospital, Paris;Cite University, Paris, France. florentia.kaguelidou@aphp.fr.;Clinical Investigations Center, Inserm CIC1426, Hopital Robert Debre, 48;boulevard Serurier, 75019, Paris, France. florentia.kaguelidou@aphp.fr.;EA7323 "Therapeutic Assessment, and Perinatal and Pediatric Pharmacology", Paris;Cite University, Paris, France.;boulevard Serurier, 75019, Paris, France.;Department of Medical and Clinical Pharmacology, Centre of Pharmacovigilance and;Pharmacoepidemiology, Faculty of Medicine, Toulouse University Hospital (CHU),;Toulouse, France.;CIC 1436, Team PEPSS (Pharmacologie En Population cohorteS et biobanqueS),;Toulouse University Hospital, Toulouse, France.;Department of Child and Adolescent Psychiatry, Robert Debre Hospital, APHP Nord,;Paris Cite University, Paris, France.;Human Genetics and Cognitive Functions, Institut Pasteur, Paris, France.;Department of Pharmacology, Regional Center of Pharmacovigilance, Cochin;Hospital, AP-HP Centre-Paris Cite University, Paris, France. |
|---|
